
News|Articles|September 1, 2003
Aloxi (Palonosetron)
5-HT3 receptor antagonist indicated to prevent delayed CINV
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
2
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
3
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
4
Racial differences in treatment priorities highlight opportunity to strengthen shared decision-making in lung cancer care
5






















































